Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice

International Journal of Neuropsychopharmacology

Volumn 12, Issue 1, 2009, Pages 61-71

  Berrocoso, Esther ^a   Mico, Juan A ^a  

^a UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

5 HT; Antidepressant like effect; Antinociceptive effect; Forced swimming test; Hot plate test; Mice; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; VENLAFAXINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; FOREBRAIN; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; METABOLISM; MOTOR ACTIVITY; PAIN ASSESSMENT; PSYCHOLOGICAL ASPECT; REACTION TIME; SWIMMING;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; PAIN MEASUREMENT; PIPERAZINES; PYRIDINES; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SWIMMING;

EID: 61949324742     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008766     Document Type: Article

References (51)

1. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F (2005). Strategies for producing faster acting antidepressants. Drug Discovery Today 10, 578-585.
2. Ardid D, Alloui A, Brousse G, Jourdan D, Picard P, Dubray C, Eschalier A (2001). Potentiation of the antinociceptive effect of clomipramine by a 5-HT(1A) antagonist in neuropathic pain in rats. British Journal of Pharmacology 132, 1118-1126.
3. Artigas F, Adell A, Celada P (2006). Pindolol augmentation of antidepressant response. Current Drug Targets 7, 139-147.
4. Barkin RL, Barkin S (2005). The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. American Journal of Therapeutics 12, 431-438.
5. Beique J, de Montigny C, Blier P, Debonnel G (2000a). Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 39, 1800-1812.
6. Beique JC, Blier P, de Montigny C, Debonnel G (2000b). Potentiation by (-)pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine. Neuropsychopharmacology 23, 294-306.
7. Berrocoso E, Mico JA (2007). In vivo effect of venlafaxine on locus coeruleus neurons: role of opioid, alpha(2)-adrenergic, and 5-hydroxytryptamine(1A) receptors. Journal of Pharmacology and Experimental Therapeutics 322, 101-107.
8. Bjorvatn B, Fornal CA, Martin FJ, Metzler CW, Jacobs BL (2000). Venlafaxine and its interaction with WAY 100635: effects on serotonergic unit activity and behavior in cats. European Journal of Pharmacology 404, 121-132.
9. Blier P, Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry 53, 193-203.
10. Bortolozzi A, Amargos-Bosch M, Toth M, Artigas F, Adell A (2004). In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice. Journal of Neurochemistry 88, 1373-1379.
11. Briley M (2004). Clinical experience with dual action antidepressants in different chronic pain syndromes. Human Psychopharmacology 19(Suppl. 1), S21-25.
12. Dawson LA, Nguyen HQ, Geiger A (1999). Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. qNeuropharmacology 38, 1153-1163.
13. Delgado PL (2004). Common pathways of depression and pain. Journal of Clinical Psychiatry 65 (Suppl. 12), 16-19.
14. Dogrul A, Seyrek M (2006). Systemic morphine produce antinociception mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. British Journal of Pharmacology 149, 498-505.
15. Eschalier A, Mestre C, Dubray C, Ardid D (1994). Why are antidepressants effective in pain relief? CNS Drugs 2, 261-267.
16. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, et al. (1996). Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behavioural Brain Research 73, 337-353.
17. Greden JF (2003). Physical symptoms of depression: unmet needs. Journal of Clinical Psychiatry 64 (Suppl. 7), 5-11.
18. Grippo AJ, Sullivan NR, Damjanoska KJ, Crane JW, Carrasco GA, Shi J, Chen Z, Garcia F, Muma NA, Van de Kar LD (2005). Chronic mild stress induces behavioral and physiological changes, and may alter serotonin 1A receptor function, in male and cycling female rats. Psychopharmacology (Berlin) 179, 769-780.
19. Guscott M, Bristow LJ, Hadingham K, Rosahl TW, Beer MS, Stanton JA, Bromidge F, Owens AP, Huscroft I, Myers J, et al. (2005). Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 48, 492-502.
20. Haddjeri N, Blier P, de Montigny C (1998). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. Journal of Neuroscience 18, 10150-10156.
21. Hammack SE, Hartley CE, Lea SE, Maier SF, Watkins LR, Sutton LC (1999). Inescapable shock-induced potentiation of morphine analgesia in rats: sites of action. Behavioral Neuroscience 113, 795-803.
22. Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG, Bonaventure P (2004). 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. European Journal of Pharmacology 487, 125-132.
23. Le Bars D, Gozariu M, Cadden SW (2001). Animal models of nociception. Pharmacological Reviews 53, 597-652.
24. Lynch ME (2001). Antidepressants as analgesics: a review of randomized controlled trials. Journal of Psychiatry and Neuroscience 26, 30-36.
25. Marchand F, Alloui A, Chapuy E, Jourdan D, Pelissier T, Ardid D, Hernandez A, Eschalier A (2003). Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain 103, 229-235.
26. Mayorga AJ, Dalvi A, Page ME, Zimov-Levinson S, Hen R, Lucki I (2001). Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. Journal of Pharmacology and Experimental Therapeutics 298, 1101-1107.
27. Mico JA, Ardid D, Berrocoso E, Eschalier A (2006a). Antidepressants and pain. Trends in Pharmacological Sciences 27, 348-354.
28. Mico JA, Berrocoso E, Ortega-Alvaro A, Gibert-Rahola J, Rojas-Corrales MO (2006b). The role of 5-HT1A receptors in research strategy for extensive pain treatment. Current Topics in Medicinal Chemistry 6, 1997-2003.
29. Millan MJ (2002). Descending control of pain. Progress in Neurobiology 66, 355-474.
30. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology and Therapeutics 110, 135-370.
31. Millan MJ, Brocco M, Veiga S, Cistarelli L, Melon C, Gobert A (1998). WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. European Journal of Pharmacology 341, 165-167.
32. Nemoto H, Toda H, Nakajima T, Hosokawa S, Okada Y, Yamamoto K, Horiuchi R, Endo K, Ida I, Mikuni M, Goto F (2003). Fluvoxamine modulates pain sensation and affective processing of pain in human brain. Neuroreport 14, 791-797.
33. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R (2005). The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45, 144-152.
34. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Archives of International Pharmacodynamics and Therapeutics 229, 327-336.
35. Price DD (2002). Central neural mechanisms that interrelate sensory and affective dimensions of pain. Molecular Interventions 2, 339, 392-403.
36. Quintero L, Moreno M, Avila C, Arcaya J, Maixner W, Suarez-Roca H (2000). Long-lasting delayed hyperalgesia after subchronic swim stress. Pharmacology Biochemistry Behavior 67, 449-458.
37. Redrobe JP, Bourin M, Colombel MC, Baker GB (1998). Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berlin), 138, 1-8.
38. Redrobe JP, MacSweeney CP, Bourin M (1996). The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. European Journal of Pharmacology 318, 213-220.
39. Riad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L (2004). Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. Journal of Neuroscience 24, 5420-5426.
40. Rojas-Corrales MO, Ortega-Alvaro A, Gibert-Rahola J, Roca-Vinardell A, Mico JA (2000). Pindolol, a beta-adrenoceptor blocker/5- hydroxytryptamine(1A/1B) antagonist, enhances the analgesic effect of tramadol. Pain 88, 119-124.
41. Rowbotham MC, Goli V, Kunz NR, Lei D (2004). Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110, 697-706.
42. Saarto T, Wiffen PJ (2007). Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews. Issue 4. Art. no.: CD005454.
43. Sayar K, Aksu G, Ak I, Tosun M (2003). Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy 37, 1561-1565.
44. Shelton RC (2007). Augmentation strategies to increase antidepressant efficacy. Journal of Clinical Psychiatry 68 (Suppl. 10), 18-22.
45. Sprouse JS, Aghajanian GK (1987). Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1, 3-9.
46. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 10, 732-747.
47. Stamford JA, Davidson C, McLaughlin DP, Hopwood SE (2000). Control of dorsal raphe 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? Trends in Neuroscience 23, 459-465.
48. Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E (2004). Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test. European Journal of Pharmacology 487, 133-142.
49. Urquhart D, Hoving J, Assendelft W, Roland M, van Tulder M (2008). Antidepressants for non-specific low back pain. Cochrane Database of Systematic Reviews. Issue 1. Art. no.: CD001703.
50. Woolfe G, McDonald AD (1944). The evaluation of the analgesic action of pethidine hydrochloride (Demerol). Journal of Pharmacology and Experimental Therapeutics 80, 300.
51. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109-110.